Welcome to our dedicated page for FATE THERAPEUTICS SEC filings (Ticker: FATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on FATE THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into FATE THERAPEUTICS's regulatory disclosures and financial reporting.
Fate Therapeutics President and CEO Bahram Valamehr reported the sale of 5,190 shares of the company’s common stock on January 9, 2026 at a weighted average price of $1.0708 per share. After this transaction, he beneficially owned 329,708 shares.
According to the filing, the shares were sold only in an amount required to cover tax withholding obligations arising from the vesting of 8,326 shares underlying previously granted RSUs. The sales were automatically executed under an irrevocable sell-to-cover election and were not made at his discretion.
Fate Therapeutics has a Form 144 notice indicating a shareholder plans to sell 10,589 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of 11,275.17. These shares were acquired on 01/08/2026 via restricted stock vesting as compensation from the issuer. Shares of common stock outstanding were 115,352,289 at the time referenced, which serves as a baseline figure.
A shareholder has filed a notice of intent to sell 5,190 shares of common stock through Fidelity Brokerage Services LLC on or about 01/09/2026, with trading on the NASDAQ exchange. The shares have an aggregate market value of $5,557.45 based on the information provided and are part of a total of 115,352,289 shares outstanding. These securities were acquired from the issuer on 01/08/2026 through restricted stock vesting as compensation, with the same date shown for acquisition and payment.
Fate Therapeutics reported Q3 2025 results. Collaboration revenue was $1.7 million, down from $3.1 million a year ago, reflecting lower recognition under its Ono collaboration. Operating expenses fell to $36.5 million from $55.5 million as R&D and G&A were reduced. Net loss narrowed to $32.3 million from $47.7 million, and loss per share improved to $0.27 from $0.40.
Liquidity and cash flows: Cash and cash equivalents were $40.6 million, with short-term investments of $174.8 million and long-term investments of $10.3 million. Total current assets were $221.3 million. Net cash used in operations for the nine months was $82.8 million, partially offset by $83.5 million net inflows from investment activity and $3.8 million from a CIRM award.
Operational updates: The company implemented an August 2025 restructuring, recording $1.1 million in severance and related costs. It recognized $1.7 million in Q3 revenue and $5.3 million year-to-date under the Ono arrangement, with committed funding through June 2026. As of November 6, 2025, 115,352,289 common shares were outstanding.
Fate Therapeutics, Inc. (FATE) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.
The disclosure was provided under Item 2.02 (Results of Operations and Financial Condition) and is being furnished, not filed, under the Exchange Act. The report was signed by President and Chief Executive Officer Bahram Valamehr.
Fate Therapeutics (FATE) reported an early clinical update for FT819, its off-the-shelf, CD19-targeted CAR T-cell candidate, in moderate-to-severe systemic lupus erythematosus. As of the September 25, 2025 data cut-off, 10 patients received a single FT819 dose in a Phase 1 study and data were highlighted at ACR Convergence 2025.
The trial evaluates FT819 with either less‑intensive conditioning (cyclophosphamide or bendamustine) or no conditioning. In the less‑intensive arm, the company observed rapid, sustained CD19+ B‑cell depletion that correlated with dose, followed by emergence of naïve B cells beyond baseline, consistent with an immune reset and reduction in disease burden. Without conditioning, reductions in CD19+ B cells and expanded B‑cell clones were seen, alongside improvements in disease activity scores.
Fate also initiated independent dose‑expansion cohorts in AAV, IIM, and SSc, and is engaging the FDA under its RMAT designation to align on a registrational study design with a goal to start a pivotal study in 2026.
Fate Therapeutics (FATE) reported a Form 4 showing its Chief Financial Officer received equity awards on 10/20/2025. The CFO was granted 75,000 restricted stock units at $0.00, which vest 25% on November 1, 2026, November 1, 2027, November 1, 2028, and November 1, 2029. The CFO also received a stock option for 375,000 shares at an exercise price of $1.54, vesting 25% on October 20, 2026 and monthly thereafter for 36 months, expiring on October 20, 2035. Following the transactions, the filing lists 75,000 common shares and 375,000 options beneficially owned.
Fate Therapeutics (FATE) filed a Form 3, the initial statement of beneficial ownership for its Chief Financial Officer under Section 16. The filing states that no securities are beneficially owned by the reporting person as of the event date 10/20/2025. The form was filed by one reporting person, with a Power of Attorney on file (Exhibit 24) and signed by Cindy Tahl, as Attorney-in-Fact on 10/21/2025.
Fate Therapeutics filed a Form S-8 to register 1,750,000 additional shares of common stock for issuance under its Amended and Restated Inducement Equity Plan.
The Board approved the increase on October 13, 2025, adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4). The filing uses General Instruction E to register additional securities and incorporates the prior S-8 (File No. 333-253459).
Pursuant to Rule 416(a), the registration also covers an indeterminate number of additional shares for anti‑dilution and other adjustments.
Fate Therapeutics (FATE) reported board and leadership changes. On October 10, 2025, John D. Mendlein and Neelufar Mozaffarian notified the company of their resignations from the Board, effective October 13, 2025. The company stated both resignations were voluntary and not due to any disagreement on operations, practices, or policies. Following these changes, the Board size was reduced from 10 to 8 directors, effective October 13, 2025.
On October 13, 2025, the Board approved the appointment of Kamal Adawi, M.S., M.B.A., as Chief Financial Officer, effective October 20, 2025. He was also designated principal financial officer and principal accounting officer, replacing Bahram Valamehr in those roles; Dr. Valamehr continues as Director and as President and Chief Executive Officer. The company furnished a press release on October 14, 2025 announcing Mr. Adawi’s appointment.